You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

CLINICAL TRIALS PROFILE FOR REVLIMID


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for REVLIMID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed University of Wisconsin, Madison Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for REVLIMID

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00056160 ↗ CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Phase 3 2003-01-01 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
NCT00056160 ↗ CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Corporation Phase 3 2003-01-01 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
NCT00067743 ↗ A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed Celgene Corporation Phase 2 2003-08-01 This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)
NCT00087672 ↗ A Phase II Study of CC-5013 in Myelofibrosis Completed Celgene Corporation Phase 2 2004-07-01 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for REVLIMID

Condition Name

Condition Name for REVLIMID
Intervention Trials
Multiple Myeloma 144
Chronic Lymphocytic Leukemia 33
Plasma Cell Myeloma 26
Lymphoma 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for REVLIMID
Intervention Trials
Multiple Myeloma 233
Neoplasms, Plasma Cell 228
Lymphoma 141
Leukemia 85
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for REVLIMID

Trials by Country

Trials by Country for REVLIMID
Location Trials
Canada 135
France 77
Spain 68
Germany 67
Italy 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for REVLIMID
Location Trials
Texas 117
California 112
New York 111
Ohio 91
Florida 83
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for REVLIMID

Clinical Trial Phase

Clinical Trial Phase for REVLIMID
Clinical Trial Phase Trials
Phase 4 5
Phase 3 59
Phase 2/Phase 3 4
[disabled in preview] 260
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for REVLIMID
Clinical Trial Phase Trials
Completed 222
Active, not recruiting 97
Terminated 91
[disabled in preview] 74
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for REVLIMID

Sponsor Name

Sponsor Name for REVLIMID
Sponsor Trials
Celgene Corporation 185
National Cancer Institute (NCI) 134
Celgene 105
[disabled in preview] 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for REVLIMID
Sponsor Trials
Other 529
Industry 486
NIH 137
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.